ABSTRACT
Since 1987, 80 hydroxyapatite-coated (HA) cementless total hip prostheses have been implanted. Thirty patients were examined 21 months postoperatively and the results compared with data for uncoated prosthesis. Earlier mobilization and freedom from pain, together with evidence of bone ingrowth without connective tissue membrane formation, confirmed the benefits of HA-coated prostheses.
Subject(s)
Femoral Neck Fractures/surgery , Hip Prosthesis , Hydroxyapatites , Osteoarthritis, Hip/surgery , Aged , Durapatite , Female , Follow-Up Studies , Humans , Male , Postoperative Complications/diagnostic imaging , Prosthesis Design , Prosthesis Failure , Radiography , Surface PropertiesSubject(s)
Bone Transplantation , Surgical Instruments , Femur Head/surgery , Hip Prosthesis , HumansABSTRACT
From three different surgical departments 78 patients with purulent peritonitis are analyzed according to cause, origin, and extent of peritonitis. Operative therapy is presented. As additional antibacterial therapy the new chemotherapeutic agent, Taurolin, with antiendotoxin-effect is used. The postoperative course (temperature exceeding 38 degrees C, secondary wound healing, day of discharge, and serious complications) is correlated with pre- and intraoperative parameters; for instance, 1. postoperative fever occurs in one half of the patients, more frequently following perforation of stomach and duodenum; 2. every second patient shows secondary wound healing, this happens even more often in peritonitis arising from biliary disease or appendicitis; 3. in 29.5% of the patients serious complications arise, especially in patients with peritonitis originating in stomach, small intestine or large bowel; 4. overall mortality of 11.5% is surpassed in patients with peritonitis originating from small intestine or large bowel. The so-called peritonitis-index (calculated on the basis of pre- and intraoperative factors) shows a significant difference between survivors and patients dying during the postoperative course. In 80% of the 78 patients with purulent peritonitis taurolin was effective as a substitute for the usual antibiotics.
Subject(s)
Peritonitis/drug therapy , Taurine/analogs & derivatives , Thiadiazines/therapeutic use , Thiazines/therapeutic use , Adult , Chemical Phenomena , Chemistry , Humans , Middle Aged , Peritonitis/complications , Peritonitis/microbiology , Peritonitis/mortality , Postoperative PeriodSubject(s)
Peritonitis/drug therapy , Taurine/analogs & derivatives , Thiadiazines/administration & dosage , Thiazines/administration & dosage , Adolescent , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Female , Humans , Injections, Intraperitoneal , Injections, Intravenous , Lung Diseases/etiology , Male , Middle Aged , Peritonitis/complications , Peritonitis/surgery , Suppuration , Thiadiazines/therapeutic useSubject(s)
Anti-Infective Agents/therapeutic use , Peritonitis/drug therapy , Taurine/therapeutic use , Thiadiazines/therapeutic use , Thiazines/therapeutic use , Animals , Anti-Bacterial Agents , Bacteria/drug effects , Biotransformation , Clinical Trials as Topic , Drug Evaluation , Fungi/drug effects , Half-Life , Humans , Mice , Rabbits , Rats , Taurine/metabolism , Taurine/pharmacology , Thiadiazines/metabolism , Thiadiazines/pharmacologyABSTRACT
The application in purulent peritonitis of a novel surgical lavaging agent with unique properties is reported. Taurolin is a non-toxic formaldehyde-transmitter with a Thiadiazine structure exhibiting a twofold action in gram-negative sepsis owing to its bactericidal potency and its ability to denature endotoxins in vivo. The present study reports the surgical treatment of 62 patients with appendicitis and peritonitis of varying genesis, using 0.5% Taurolin as lavaging and 2% Taurolin as instillation agents. After 5 days 22 out of 25 patients with purulent peritonitis were void of intraperitoneal bacteria. To date no significant adverse drug reactions were observed.
